NovaBridge Biosciences Accumulated Other Comprehensive Income
NovaBridge Biosciences (NBP) had Accumulated Other Comprehensive Income of $41.55 million as of 2025-12-31, per its 20-F filed 2026-04-07.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-04-07
- 2023-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax 298.29M CNY.
- 2022-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax 213.79M CNY.
- 2022-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax 47.05M CNY.
- 2021-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -186.51M CNY.
CNY
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2023-12-31 | 298.29M CNY 20-F · filed 2024-04-30 |
| 2022-12-31 | 213.79M CNY 20-F · filed 2024-04-30 |
| 2022-06-30 | 47.05M CNY 6-K · filed 2022-11-10 |
| 2021-12-31 | -186.51M CNY 20-F · filed 2023-05-01 |
| 2020-12-31 | -50.79M CNY 20-F · filed 2022-04-29 |
| 2020-09-30 | 85.66M CNY 6-K · filed 2021-02-05 |
| 2019-12-31 | 70.13M CNY 20-F · filed 2021-04-28 |
| 2018-12-31 | 59.38M CNY 20-F · filed 2020-04-29 |
USD
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax | Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed |
|---|---|---|
| 2025-12-31 | $41.55M 20-F · filed 2026-04-07 | |
| 2025-09-30 | $42.89M 6-K · filed 2025-12-18 | |
| 2025-06-30 | $37.04M 6-K · filed 2025-10-06 | |
| 2024-12-31 | $33.38M 20-F · filed 2026-04-07 | |
| 2023-12-31 | $39.77M 20-F · filed 2025-04-03 | $42.01M 20-F · filed 2024-04-30 |
| 2022-12-31 | $31.00M 20-F · filed 2023-05-01 | |
| 2022-06-30 | $7.03M 6-K · filed 2022-11-10 | |
| 2021-12-31 | -$29.27M 20-F · filed 2022-04-29 | |
| 2020-12-31 | -$7.78M 20-F · filed 2021-04-28 | |
| 2020-09-30 | $12.62M 6-K · filed 2021-02-05 | |
| 2019-12-31 | $10.07M 20-F · filed 2020-04-29 |